Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07387666 · ClinicalTrials.gov registry record · Early Phase 1
Imaging Acetadote Metabolism in Glioblastoma
A Early Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT07387666 is a Early Phase 1 study that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT07387666, a Early Phase 1 study, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This goal of this clinical trial is to evaluate how Acetadote affects metabolism in patients with glioblastoma. Drugs like Acetadote, which affect the level of damage in a cell (oxidative stress), may impact brain tumor metabolism and slow the growth of brain tumors. The investigators are evaluating how Acetadote affects glioblastoma metabolism by using MRI-based methods and by determining the changes in metabolism in brain tumor tissue resected from patients with a new diagnosis of glioblastoma.
Interventions
- DRUG Acetadote
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-06-18 |
| Est. Completion | 2028-07-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07387666
The ClinicalTrials.gov registry entry for NCT07387666 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acetadote is the first listed.
NCT07387666 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07387666 about?
NCT07387666 is a clinical study titled "Imaging Acetadote Metabolism in Glioblastoma". This goal of this clinical trial is to evaluate how Acetadote affects metabolism in patients with glioblastoma. Drugs like Acetadote, which affect the level of damage in a cell (oxidative stress), may impact brain tumor metabolism and slow the growth of brain tumors. The investigators are evaluatin...
What is the current status of trial NCT07387666?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2026-06-18. Estimated completion is 2028-07-01.
What interventions are being tested in trial NCT07387666?
The interventions under investigation include: Acetadote (DRUG).
Who is sponsoring clinical trial NCT07387666?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.